DMRA — Damora Therapeutics Share News
0.000.00%
Last trade - 00:00Galecto Inc reports results for the quarter ended in September - Earnings Summary
Brief: Galecto Reports Third Quarter Results
Galecto Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Galecto To Present Topline Data From Clinical Trial Showing GB1211 Reduced Signs Of Liver Impairment At AASLD's The Liver Meeting 2022
Galecto Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Galecto Inc Entered Into Collaboration Agreement For Investigator-Initiated Phase 2
Galecto drops as bone marrow cancer drug data raises concerns
Brief: Galecto Says GB2064 Shows Reduction In Fibrosis Of Bone Marrow In Patients With Myelofibrosis, Validating LOXL2 As A Clinical Fibrosis Target
Galecto Inc reports results for the quarter ended in June - Earnings Summary
Galecto Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Galecto Reports Second Quarter Operating And Financial Results
Brief: Galecto Inc Says First Patient Enrolled In Phase 2 Trial Of GB1211 In Combination With Atezolizumab For First-Line Treatment Of NSCLC
Brief: Galecto Reports First Quarter Operating And Financial Results
Brief: Galecto Completes Enrollment In Global Trial Of GB0139 for Treatment of IPF
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Brief: Galecto Says Top-Line Results From GULLIVER-2 Trial On Track For Q4
Brief: Galecto Reports Financial Results For The Year Ended December 31, 2021
Brief: Galecto Publishes Results Showing Safety And Efficacy Of The Gb0139 Inhaled Galectin-3 Inhibitor In Hospitalized Covid-19 Patients On Standard Of Care